Results 131 to 140 of about 957 (170)
<i>In vitro</i> evolution of durlobactam resistance in NDM-producing <i>Escherichia coli</i> due to a single mutation in <i>mrdA</i> encoding penicillin-binding protein 2. [PDF]
Antimicrob Agents ChemotherMcElheny CL +5 more
europepmc +1 more source
Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance. [PDF]
J MicrobiolPark SB, Kim MY, Cha SS.
europepmc +1 more source
Journal of Clinical Medicine, 2022 A. baumannii is a frequent cause of difficult-to-treat healthcare-associated infections. The use of a novel beta-lactamase inhibitor, durlobactam, has been proposed against multidrug-resistant A. baumannii. A systematic review of studies assessing the efficacy and safety of durlobactam in the treatment of multidrug-resistant A. baumannii infections was
Guido Granata +2 more
exaly +4 more sources
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii
Antibiotics, 2023 Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Emanuele Durante-Mangoni +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
Annals of Pharmacotherapy, 2023Objective: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Data Sources: PubMed databases and ...
Benjamin August +2 more
openaire +2 more sources
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).
openaire +2 more sources
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex
Expert Review of Anti-Infective TherapyInfections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.This review provides a comprehensive discussion of ...
Anthony Guarascio, Jordan Covvey
exaly +3 more sources